Engineers Gate Manager’s Arbutus Biopharma ABUS Stock Holding History

Engineers Gate Manager’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-29,600	Closed	-$93K	–	1655
2020 Q3	$93K	Buy	+29,600	New	+$90K	﹤0.01%	1567

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Engineers Gate Manager's ABUS Position: Q4 2020 in Review

Engineers Gate Manager sold out of Arbutus Biopharma (ABUS) in Q4 2020, closing a stake of 29,600 shares — an estimated $93K sold.

Engineers Gate Manager first reported a position in ABUS in Q3 2020 and held it in 1 quarter. The position peaked at $93K in Q3 2020. 80 funds tracked by Wall St. Rank hold ABUS as of Q4 2020.

Engineers Gate Manager reported no remaining Arbutus Biopharma position as of Q4 2020 after selling out during the quarter.
Engineers Gate Manager sold 29,600 Arbutus Biopharma shares in Q4 2020, an estimated $93K.
Engineers Gate Manager first reported a position in Arbutus Biopharma in Q3 2020 and held it in 1 quarter.
Engineers Gate Manager's Arbutus Biopharma position peaked at $93K in Q3 2020.
80 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2020.

Based on Engineers Gate Manager's 13F filing for Q4 2020, filed 16 Feb 2021.